Compounding Pharmacy Market Set for Growth Toward $21 Billion by 2031

Demand for customized medications is reshaping the industry, particularly as providers look to fill supply gaps for GLP-1 drugs and address the requirements of pediatric and geriatric patients. Pharmaceutical dosage alteration remains the dominant segment, allowing pharmacists to tailor concentrations and delivery methods—such as gels or injections—for individuals who cannot utilize standard commercial options. Hormone replacement therapy is currently identified as the fastest-growing therapeutic application, fueled by a rise in endocrine disorders and a preference for bioidentical formulations.

North America currently leads the global landscape, commanding a 43.5% market share in 2025. This dominance is supported by robust regulatory frameworks and a sophisticated healthcare infrastructure that prioritizes patient-specific therapies. While the market remains fragmented—with top players like Baxter, Fagron, and B. Braun holding roughly 15–20% of the total share—strategic consolidation is accelerating. Recent acquisitions, such as Fagron’s purchase of University Compounding Pharmacy for $41.5 million, reflect a broader industry push to scale 503A and 503B capabilities, improve automation, and secure reliable supply chains for hospitals and specialty clinics.